going from semaglutide to tirzepatide Switching Switching from Semaglutide to Tirzepatide:

Dual-Agonist Comparisons Tirzepatide (found in medications like Mounjaro) targets two receptors: GLP-1 and GIP

It has now surpassed viral liver disease to become the worlds most common liver disease, increasing the imminence of more basic and clinical research

GLP-1/glucagon co-agonists The development of these unimolecular formulations targeting both GLP-1 and glucagon receptors enhances the anorectic effect of GLP-1, provides a lipolytic and lipogenesis-inhibiting effect (Table 2)particularly at the hepatic leveland promotes thermogenic activity, thereby facilitating weight reduction and the treatment of MASLD.1,5,35 Survodutide generates dose-dependent weight reduction of up to 14.9% in 46 weeks.49 It is shown to be effective in reducing liver fat and improving MASH in up to 62% of participants treated with weekly injection of 4.8 mg

The US adult obesity rate was about 40% from 2017 to 2020, and Goldman Sachs researchers estimated last year that the drugs could be prescribed to 15 million Americans by 2030

Some refrigerator models may run colder in the back while the doors may run warmer, making the middle the safest place to store Zepbound pens

What makes this especially frustrating is that the people most affected by these contracts are often already stretched thin